Advertisement

Topics

Search Results for "Colchicine And Rivaroxaban"

11:36 EDT 28th September 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Does Colchicine Prevent Adverse Cardiovascular Events in Gout Patients?

This retrospective study suggests that anti-inflammatory therapies, such as colchicine, are associated with lower CV risk.

Rivaroxaban in the Real World

A large Phase IV registry study shows that rivaroxaban is associated with a very low incidence of major bleeding, death, or stroke. Also, adherence to therapy was much higher than observed in other st...

Rivaroxaban Saves Hospitals Money for VTE Admissions: Study

U.S. hospitals save money when they use the novel oral anticoagulant rivaroxaban instead of warfarin to treat patients with venous thromboembolism (VTE), a new analysis finds. Reuters Health Informa...

Rivaroxaban: new tool for antiphospholipid syndrome (lupus condition)

Rivaroxaban could be a safe treatment option for antiphospholipid syndrome, an important finding for people with lupus, says research published in The Lancet Haematology. Thrombotic antiphospholipid s...

Treatment with colchicine is not linked to reducing cardiovascular mortality

An evidence review of 39 clinical trials found that patients who received continuous long-term treatment with colchicine had no reduction in all-cause mortality or cardiovascular mortality.

BRIEF-Hikma says U.S. Court of Appeals upholds regulatory approval of colchicine

* Fda's regulatory approval of hikma's colchicine 0.6 mg capsule product was upheld.

Colchicine and Prevention of Cardiovascular Events

This Clinical Evidence Synopsis summarizes a Cochrane review of clinical trials comparing the effects of long-term colchicine treatment with usual care or placebo on cardiovascular events in patients ...

Meta-analysis: Colchicine cuts risk of pericarditis recurrence

(HealthDay)—Colchicine is effective and reduces the risk of pericarditis recurrence/post-pericardiotomy syndrome, according to a meta-analysis published online Aug. 31 in Cardiovascular Therapeutics...

Matching PubMed Articles

Colchicine for prevention and treatment of cardiac diseases: a meta-analysis.

Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all randomized controlled trials that assess the use of colchicine for the pre...

Colchicine for prevention of cardiovascular events.

Colchicine is an anti-inflammatory drug that is used for a wide range of inflammatory diseases. Cardiovascular disease also has an inflammatory component but the effects of colchicine on cardiovascula...

Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.

The aims of this study were to investigate the effects of rivaroxaban on routine coagulation assays using our local, widely available, reagents and to study the relationship between sensitive coagulat...

A high performance thin layer chromatographic method for the estimation of colchicine in different formulations.

Colchicine is a main alkaloid present in bitter and sweet variety of colchicum (Colchicum luteum Baker), which have been reported to possess anti-rheumatic, anti-gout, and anticancer potential. Colchi...

Colchicine and Prevention of Cardiovascular Events.

Is continuous long-term treatment with colchicine associated with lower rates of all-cause mortality and myocardial infarction and higher rates of adverse events?

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement